WO2006000448A3 - Fc-INTERFERON-BETA FUSION PROTEINS - Google Patents

Fc-INTERFERON-BETA FUSION PROTEINS Download PDF

Info

Publication number
WO2006000448A3
WO2006000448A3 PCT/EP2005/006925 EP2005006925W WO2006000448A3 WO 2006000448 A3 WO2006000448 A3 WO 2006000448A3 EP 2005006925 W EP2005006925 W EP 2005006925W WO 2006000448 A3 WO2006000448 A3 WO 2006000448A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
interferon
beta
ifn
nucleic acid
Prior art date
Application number
PCT/EP2005/006925
Other languages
French (fr)
Other versions
WO2006000448A2 (en
Inventor
Stephen D Gillies
Nigel John Watkins
Matthew Paul Baker
King-Ming Lo
Original Assignee
Merck Patent Gmbh
Stephen D Gillies
Nigel John Watkins
Matthew Paul Baker
King-Ming Lo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Stephen D Gillies, Nigel John Watkins, Matthew Paul Baker, King-Ming Lo filed Critical Merck Patent Gmbh
Priority to AT05766761T priority Critical patent/ATE443720T1/en
Priority to AU2005256519A priority patent/AU2005256519B2/en
Priority to DE602005016799T priority patent/DE602005016799D1/en
Priority to JP2007517216A priority patent/JP4808709B2/en
Priority to EP05766761A priority patent/EP1761559B1/en
Priority to CA2572015A priority patent/CA2572015C/en
Publication of WO2006000448A2 publication Critical patent/WO2006000448A2/en
Publication of WO2006000448A3 publication Critical patent/WO2006000448A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc- IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using the fusion proteins and/or nucleic acid molecules for treating diseases and conditions alleviated by the administration of interferon-beta.
PCT/EP2005/006925 2004-06-28 2005-06-28 Fc-INTERFERON-BETA FUSION PROTEINS WO2006000448A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT05766761T ATE443720T1 (en) 2004-06-28 2005-06-28 FC-INTERFERON-BETA FUSION PROTEINS
AU2005256519A AU2005256519B2 (en) 2004-06-28 2005-06-28 Fc-interferon-beta fusion proteins
DE602005016799T DE602005016799D1 (en) 2004-06-28 2005-06-28 FC INTERFERON BETA FUSION PROTEINS
JP2007517216A JP4808709B2 (en) 2004-06-28 2005-06-28 Fc-interferon-beta fusion protein
EP05766761A EP1761559B1 (en) 2004-06-28 2005-06-28 Fc-INTERFERON-BETA FUSION PROTEINS
CA2572015A CA2572015C (en) 2004-06-28 2005-06-28 Fc-interferon-beta fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58338904P 2004-06-28 2004-06-28
US60/583,389 2004-06-28

Publications (2)

Publication Number Publication Date
WO2006000448A2 WO2006000448A2 (en) 2006-01-05
WO2006000448A3 true WO2006000448A3 (en) 2006-03-02

Family

ID=35429166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/006925 WO2006000448A2 (en) 2004-06-28 2005-06-28 Fc-INTERFERON-BETA FUSION PROTEINS

Country Status (9)

Country Link
US (3) US7670595B2 (en)
EP (1) EP1761559B1 (en)
JP (1) JP4808709B2 (en)
AT (1) ATE443720T1 (en)
AU (1) AU2005256519B2 (en)
CA (1) CA2572015C (en)
DE (1) DE602005016799D1 (en)
ES (1) ES2332924T3 (en)
WO (1) WO2006000448A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570836A (en) * 2013-10-25 2014-02-12 江苏众红生物工程创药研究院有限公司 Recombinant porcine interferon beta1-Fc fusion protein as well as encoding gene and expressing method thereof
CN104530213A (en) * 2014-11-24 2015-04-22 广西大学 Viral hepatitis treatment drug interferon production technology

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5179689B2 (en) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Enhancing the half-life of antibody-based fusion proteins in the circulation
WO2002072605A2 (en) 2001-03-07 2002-09-19 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
CA2446087C (en) 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
DE602004013372T2 (en) 2003-12-30 2009-07-02 Merck Patent Gmbh IL-7 FUSION PROTEINS WITH ANTIBODY PORTIONS, THEIR PREPARATION AND THEIR USE
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
KR20080021614A (en) * 2005-05-26 2008-03-07 쉐링 코포레이션 Interferon-igg fusion
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
EP1966245B1 (en) 2005-12-30 2011-05-18 Merck Patent GmbH Anti-cd19 antibodies with reduced immunogenicity
CN101351475B (en) * 2005-12-30 2013-05-15 默克专利有限公司 Interleukin-12p40 variants with improved stability
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
FR2907454B1 (en) * 2006-10-18 2009-01-23 Biomethodes Sa IMPROVED VARIANTS OF INTERFERON BETA HUMAIN
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
ES2566385T3 (en) 2007-02-12 2016-04-12 Csl Behring Gmbh Therapeutic application of serine protease inhibitors of the Kazal type
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
CA2699944C (en) 2007-09-21 2017-11-14 The Regents Of The University Of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
ES2400107T3 (en) * 2007-10-22 2013-04-05 Merck Serono S.A. Single IFN-beta fused to an Fc fragment of mutated lgG
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
AU2010234743A1 (en) 2009-03-31 2011-10-20 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR20120030383A (en) * 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 Antibody fusion proteins with modified fcrn binding sites
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
WO2011098644A2 (en) 2010-02-09 2011-08-18 Proyecto De Biomedicina Cima, S.L. Compositions for the treatment of infectious and tumoural diseases
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
AR080993A1 (en) * 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd FORMULATION OF PROLONGED BETA INTERFERTION ACTION WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
CN102380091A (en) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
WO2012065059A2 (en) * 2010-11-12 2012-05-18 The General Hospital Corporation Treatment of atherosclerosis with bmp-alk3 antagonists
CN102585013B (en) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 Fusion protein containing omega interferon and method for preparing same
US9803210B2 (en) 2011-02-11 2017-10-31 Research Corporation Technologies, Inc. Fusion proteins comprising immunoglobulin constant domain-derived scaffolds
WO2012120128A1 (en) 2011-03-09 2012-09-13 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
JP5977814B2 (en) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド Method for treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
CN111671918A (en) 2011-06-08 2020-09-18 川斯勒佰尔公司 Lipid nanoparticle compositions and methods for MRNA delivery
NZ756727A (en) 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
KR20130049671A (en) 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
US8936782B2 (en) * 2011-11-22 2015-01-20 Cedars-Sinai Medical Center Interferon beta as antibacterial agents
CN103182072B (en) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases
WO2013103981A1 (en) * 2012-01-06 2013-07-11 Ember Therapeutics, Inc. Compositions and methods of use of fndc5 polypeptides
EA201491413A1 (en) 2012-01-26 2015-03-31 Эмджен Инк. POLYPEPTIDE GROWTH FACTOR AND DIFFERENTIATION 15 (GDF-15)
DK2814502T3 (en) 2012-02-15 2017-12-18 Csl Behring Gmbh Von Willebrand Factor variants with improved Factor VIII binding affinity
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
AU2013359907B2 (en) 2012-12-11 2018-01-18 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (en) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド Compositions and methods of use in the treatment of metabolic disorders
WO2014124217A1 (en) * 2013-02-07 2014-08-14 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
EP2958584A1 (en) 2013-02-20 2015-12-30 Yeda Research and Development Co., Ltd. Interferon treatment targeting mutant p53 expressing cells
JP6636334B2 (en) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Treatment and prevention of remote ischemia-reperfusion injury
WO2014159813A1 (en) * 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20160184458A1 (en) * 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
TR201901310T4 (en) 2013-03-14 2019-02-21 Translate Bio Inc Methods of purification of messenger RNA.
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh Cftr mrna compositions and related methods and uses
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
DK3677591T3 (en) 2013-04-29 2023-03-20 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
DK3027642T3 (en) * 2013-07-31 2020-11-02 Amgen Inc GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) CONSTRUCTIONS
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
WO2015061491A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
AU2015213988B2 (en) 2014-02-10 2019-07-11 Merck Patent Gmbh Targeted TGFbeta inhibition
US9738702B2 (en) * 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
EA201691795A1 (en) * 2014-03-31 2017-03-31 Ханми Фарм. Ко., Лтд. A METHOD FOR IMPROVING THE SOLUBILITY OF PROTEIN AND PEPTIDE AT THE EXPENSE OF USING A BINDING WITH THE FRAGMENT OF IMMUNOGLOBULIN
CN106164248B (en) 2014-04-25 2019-10-15 川斯勒佰尔公司 The purification process of mRNA
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
ES2770330T3 (en) * 2014-06-18 2020-07-01 Albert Einstein College Of Medicine Syntac polypeptides and their uses
BR112016030950A2 (en) 2014-07-02 2018-03-27 Csl Ltd modified factor viii binding polypeptide, complex, pharmaceutical composition, methods for treating a coagulopathy, to produce a polypeptide comprising a modified vwf, and to increase vwf factor viii binding affinity and factor viii half-life, use of a modified polypeptide or complex, polynucleotide, plasmid or vector, and host cell.
MX370115B (en) 2014-07-30 2019-12-02 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders.
US10287336B2 (en) 2014-09-18 2019-05-14 AskGene Pharma, Inc. Feline erythropoietin receptor agonists
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
MX357994B (en) 2014-10-31 2018-08-01 Ngm Biopharmaceuticals Inc COMPOSITIONS and METHODS OF USE FOR TREATING METABOLIC DISORDERS.
KR101838919B1 (en) * 2015-03-03 2018-03-15 에이비온 주식회사 Immunocytokine conjugated with human interferon beta-mutein and method for preparing thereof
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
MX2017014503A (en) 2015-05-22 2018-08-01 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia.
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
AU2016335912B2 (en) * 2015-10-05 2023-08-31 Circle33 Llc Antibodies with improved stability to intestinal digestion
EP3184149A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Soluble glycoprotein v for treating thrombotic diseases
CA3010720A1 (en) 2016-01-07 2017-07-13 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
US10808023B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated von Willebrand factor
ES2930351T3 (en) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd An IL-22 dimer for use in the treatment of necrotizing enterocolitis
SG11201808552XA (en) 2016-05-18 2018-10-30 Cue Biopharma Inc T-cell modulatory multimeric polypeptides and methods of use thereof
EP3458095A4 (en) 2016-05-18 2019-11-27 Albert Einstein College of Medicine Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
WO2018052615A1 (en) * 2016-08-15 2018-03-22 Cornell University Apom-fc fusion proteins, complexes thereof with sphingosine l-phosphate (sip), and methods for treating vascular and non-vascular diseases
ES2908008T3 (en) 2016-11-11 2022-04-27 CSL Behring Lengnau AG Truncated von Willebrand Factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
SG11201903950UA (en) 2016-11-11 2019-05-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20190352363A1 (en) 2016-12-22 2019-11-21 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
EP3596118A4 (en) 2017-03-15 2021-04-07 Cue Biopharma, Inc. Methods for modulating an immune response
EP3604538A4 (en) 2017-03-29 2020-12-30 University of Miyazaki Long-acting adrenomedullin derivative
MA49131A (en) * 2017-04-21 2020-03-25 Hoffmann La Roche USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF DISEASE
WO2018213476A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
EP3641800B1 (en) 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MA52205A (en) 2018-04-09 2021-02-17 Amgen Inc GROWTH DIFFERENTIATION FACTOR FUSION PROTEINS 15
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
KR20220009984A (en) 2019-05-17 2022-01-25 유니베르시태트 취리히 Haptoglobin for use in the treatment of secondary neurological adverse events after hemorrhagic stroke
KR20220029733A (en) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 truncated von Willebrand factor (VWF) to increase the in vitro stability of coagulation factor VIII
JP2023500953A (en) 2019-11-11 2023-01-11 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト Polypeptides for inducing tolerance to factor VIII
EP4069280A4 (en) 2019-12-02 2024-01-03 Univ Hong Kong Polytechnic Methods for inducing intermittent fasting and modulating autophagy
EP4144761A1 (en) * 2020-04-29 2023-03-08 GenoPharm Inc. Recombinant protein having fused interferon-beta mutein and antibody, and pharmaceutical composition comprising same
BR112022022035A2 (en) * 2020-04-29 2023-01-03 Abion Inc HUMAN INTERFERON-BETA VARIANT, POLYNUCLEOTIDE, EXPRESSION VECTOR, TRANSFORMED ANIMAL CELL, METHODS FOR PREPARING A HUMAN INTERFERON-BETA VARIANT, IMPROVING THE STABILITY OF A HUMAN INTERFERON-BETA R27T VARIANT, AND TREAT A DISEASE, PHARMACEUTICAL COMPOSITION AND USE
TW202208395A (en) 2020-05-12 2022-03-01 美商信號生物製藥公司 Multimeric t-cell modulatory polypeptides and methods of use thereof
CA3206884A1 (en) 2021-02-01 2022-08-04 Kevin AKERET Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
JPWO2022177018A1 (en) * 2021-02-22 2022-08-25
CN117321074A (en) 2021-05-07 2023-12-29 瑞士杰特贝林生物制品有限公司 Expression system for producing recombinant haptoglobin (Hp) beta chain
WO2023039242A2 (en) * 2021-09-13 2023-03-16 Achelois Biopharma, Inc. Multivalent interferon particles compositions and methods of use
WO2024047219A1 (en) 2022-09-02 2024-03-07 Csl Behring Ag Haptoglobin for use in treating or preventing exaggerated erectile response or erectile dysfunction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469797A (en) * 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
ATE243754T1 (en) 1987-05-21 2003-07-15 Micromet Ag MULTIFUNCTIONAL PROTEINS WITH PREDEFINED TARGET
DE3853740T2 (en) 1987-06-10 1995-11-09 Dana Farber Cancer Inst Inc Bifunctional antibody designs and methods for the selective killing of cell populations.
US5064646A (en) 1988-08-02 1991-11-12 The University Of Maryland Novel infectious bursal disease virus
EP0305967B1 (en) 1987-09-02 1993-05-05 Ciba-Geigy Ag Conjugates of interferon alpha with immunoglobulins
ES2058199T3 (en) 1987-09-23 1994-11-01 Bristol Myers Squibb Co ANTIBODY HETEROCONJUGATES FOR THE ELIMINATION OF HIV-INFECTED CELLS.
PT88641B (en) 1987-10-02 1993-04-30 Genentech Inc METHOD FOR PREPARING A VARIETY OF ADHESION
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
CA1341588C (en) 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
IE62463B1 (en) 1988-07-07 1995-02-08 Res Dev Foundation Immunoconjugates for cancer diagnosis and therapy
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5242824A (en) 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US6750329B1 (en) * 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ATE123065T1 (en) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd PROTEINS AND THEIR PRODUCTION.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
AU666866B2 (en) 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) * 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
WO1993024135A1 (en) * 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
DE4228839A1 (en) * 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
DK0706799T3 (en) 1994-09-16 2002-02-25 Merck Patent Gmbh Immune Conjugates II
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
CA2214629C (en) * 1995-03-10 2001-07-10 Genentech, Inc. Receptor activation by gas6
US6620413B1 (en) * 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ES2176574T3 (en) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY.
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
RU2217168C2 (en) * 1998-04-17 2003-11-27 Лексиген Фармасьютикэлс Корпорейшн Enhancement of immune response mediated by proteins fused of antibody and cytokine by means of combined administration of prostaglandin inhibitor
EP1088888A4 (en) 1998-05-14 2005-03-16 Merck Patent Gmbh Fused protein
US20020142374A1 (en) * 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
JP2002523036A (en) * 1998-08-25 2002-07-30 レキシジェン ファーマシューティカルズ コーポレイション Expression and transport of angiogenesis inhibitors as immunofusins
US6646113B1 (en) * 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) * 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
US6500641B1 (en) * 1999-05-06 2002-12-31 Wake Forest University School Of Medicine Compositions and methods for identifying antigens which elicit an immune response
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200479B1 (en) * 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
AU2154401A (en) * 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
JP5179689B2 (en) * 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Enhancing the half-life of antibody-based fusion proteins in the circulation
PT1257297E (en) * 2000-02-24 2006-12-29 Philogen Spa Compositions and methods for treatemnt of angiogenesis in pathological lesions
WO2001088117A2 (en) * 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
WO2002002143A2 (en) * 2000-06-29 2002-01-10 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
HUP0401300A3 (en) * 2001-01-18 2005-06-28 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
CN100404673C (en) * 2001-02-19 2008-07-23 默克专利有限公司 Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
PL362324A1 (en) * 2001-02-19 2004-10-18 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
WO2002072605A2 (en) * 2001-03-07 2002-09-19 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE10119338A1 (en) * 2001-04-20 2002-10-24 Clariant Gmbh Use of copolymers based on acrylamidoalkylsulfonic acids as thickeners in preparations containing organic solvents
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp A follistatin domain containing protein
US6938440B2 (en) * 2002-11-01 2005-09-06 Michele Smith Designs, Inc. Jewelry distribution and display combination and kit
PT1572748E (en) * 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
DE602004013372T2 (en) 2003-12-30 2009-07-02 Merck Patent Gmbh IL-7 FUSION PROTEINS WITH ANTIBODY PORTIONS, THEIR PREPARATION AND THEIR USE
DK1699821T3 (en) 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
EP1819728B1 (en) * 2004-12-09 2010-04-21 MERCK PATENT GmbH Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
JP2009521909A (en) * 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Anti-IL-6 antibody that inhibits binding of IL-6 and IL-6Rα complex to gp130
CN101351475B (en) * 2005-12-30 2013-05-15 默克专利有限公司 Interleukin-12p40 variants with improved stability
EP1966245B1 (en) * 2005-12-30 2011-05-18 Merck Patent GmbH Anti-cd19 antibodies with reduced immunogenicity
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
EP2038417A2 (en) * 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2000069913A1 (en) * 1999-05-19 2000-11-23 Lexigen Pharmaceuticals Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
WO2002074783A2 (en) * 2001-03-15 2002-09-26 Merck Patent Gmbh Modified interferon beta with reduced immunogenicity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAY C ET AL: "ENGINEERED DISULFIDE BOND GREATLY INCREASES SPECIFIC ACTIVITY OF RECOMBINANT MURINE INTERFERON- BETA", JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 12, no. 2, 1 April 1992 (1992-04-01), pages 139 - 143, XP000647532, ISSN: 0197-8357 *
LO K-M ET AL: "High level expression and secretion of Fc-X fusion proteins in mammalian cells", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 6, June 1998 (1998-06-01), pages 495 - 500, XP002125745, ISSN: 0269-2139 *
RUNKEL LAURA ET AL: "Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 39, no. 10, 14 March 2000 (2000-03-14), pages 2538 - 2551, XP002160244, ISSN: 0006-2960 *
STEWART A G ET AL: "CHEMICAL MUTAGENESIS OF HUMAN INTERFERON-BETA: CONSTRUCTION, EXPRESSION IN E. COLI, AND BIOLOGICAL ACTIVITY OF SODIUM BISULFITE-INDUCED MUTATIONS", DNA, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 6, no. 2, April 1987 (1987-04-01), pages 119 - 128, XP009004161, ISSN: 0198-0238 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103570836A (en) * 2013-10-25 2014-02-12 江苏众红生物工程创药研究院有限公司 Recombinant porcine interferon beta1-Fc fusion protein as well as encoding gene and expressing method thereof
CN103570836B (en) * 2013-10-25 2016-03-16 江苏众红生物工程创药研究院有限公司 A kind of Recombinant Swine interferon beta 1-Fc fusion rotein and encoding gene thereof and expression method
CN104530213A (en) * 2014-11-24 2015-04-22 广西大学 Viral hepatitis treatment drug interferon production technology

Also Published As

Publication number Publication date
DE602005016799D1 (en) 2009-11-05
WO2006000448A2 (en) 2006-01-05
CA2572015A1 (en) 2006-01-05
US8557232B2 (en) 2013-10-15
US7670595B2 (en) 2010-03-02
EP1761559A2 (en) 2007-03-14
CA2572015C (en) 2014-04-22
US20060228332A1 (en) 2006-10-12
JP2008508862A (en) 2008-03-27
ES2332924T3 (en) 2010-02-15
ATE443720T1 (en) 2009-10-15
JP4808709B2 (en) 2011-11-02
AU2005256519A1 (en) 2006-01-05
EP1761559B1 (en) 2009-09-23
AU2005256519B2 (en) 2011-10-13
US20140005361A1 (en) 2014-01-02
US20090191154A1 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
WO2006000448A3 (en) Fc-INTERFERON-BETA FUSION PROTEINS
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
WO2005077042A3 (en) Albumin fusion proteins
WO2007021494A3 (en) Albumin fusion proteins
BRPI0411112A (en) heterologous fusion protein, polynucleotide, vector, host cell, process for producing a heterologous fusion protein, method for treating a patient, and use of heterologous fusion protein
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
WO2005063820A3 (en) Il-7 fusion proteins
MX2009002816A (en) Albumin fusion proteins.
AU2003263552A1 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE60311567D1 (en) TRICYCLIC PYRAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS ANTITUMOR AGENTS
WO2007146038A3 (en) Albumin fusion proteins
WO2001079442A3 (en) Albumin fusion proteins
ES2353814T3 (en) RECOMBINANT N-GLYCOSILATED PROTEINS OF PROCEDURAL CELLS.
EA200500019A1 (en) XYLANASE, ENCODING THEIR NUCLEIC ACIDS AND METHODS OF THEIR RECEIVING AND APPLICATION
DE10290072D2 (en) Modular transfection systems
WO2005037211A3 (en) Methods and compositions for the treatment of neurological disease
WO2001068854A3 (en) Fibroblast growth factor-like molecules and uses thereof
WO2003097810A3 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
WO2007149594A3 (en) Modified ribonucleases
MXPA05008688A (en) Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
WO2006047728A3 (en) Bmp gene and fusion protein
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
ATE460431T1 (en) NON-NEUTRALIZING ANTI-APC ANTIBODIES
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis
WO2006122971A3 (en) Treatment of disease using an improved regulated expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005766761

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2572015

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007517216

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005256519

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005256519

Country of ref document: AU

Date of ref document: 20050628

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005256519

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005766761

Country of ref document: EP